Kiai Parsa purchased $1.1M of MED (indirect holdings)
Kiai Parsa purchased 94,036 indirectly-held shares of MEDIFAST INC (MED) at an average of $12.06 ($12.05–$12.16, $1.13M total) across 4 trades over 2026-11-18 to 2026-11-19.
How this was made
The 30-second read
Why it matters
Traders may briefly re-rate sentiment based on insider accumulation, but the filing does not introduce new operating, financial, or strategic information.
Market read
A director’s $1.13M indirect purchase is a modest sentiment input, but it is not a standalone fundamental catalyst.
What to watch
The filing does not provide rationale, and the price range ($12.0464 to $12.1613) suggests execution near prevailing market levels, limiting inference about near-term fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Medifast, Inc., reported by director Kiai Parsa with indirect holdings.
Ticker impact
Director Kiai Parsa bought $1.13M of MED via indirect holdings, filing a Form 4 for 94,036 shares at about $12.06 weighted average.
Likely mild upward bias as traders note insider accumulation, with limited follow-through absent other company-specific news.
The disclosure is a primary SEC Form 4, but the transaction is an insider purchase without accompanying guidance, deal, or operational change.
Market effects
Minimal, as this is single-company insider activity with no sector-wide operational or regulatory change.
None indicated.
None indicated.
Counterpoint
Because the purchase is indirect and not under a 10b5-1 plan, it may reflect personal liquidity or tax/estate structuring rather than a strong forward-looking view.
Key entities
- issuerMEDIFAST INC
US-listed issuer referenced in the Form 4 insider transaction.
- insiderKiai Parsa
Director who purchased MED shares via indirect holdings.



